Roche First-Quarter Revenue Rises on U.S. Tamiflu Sales

Flu-stricken Americans and rising cancer drug sales helped Roche Holding AG boost revenue by 5.1 percent in a first quarter marked by approvals for two new breast-tumor drugs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.